Validated platform across more than 8 peer-reviewed publications

We take the opportunity to work with forward looking researchers to demonstrate the clinical value of our platform to patients, physicians and healthcare systems. And we are just getting started.

Clinical Evidence

NuvoAir Home respiratory platform supports remote monitoring of asthma patients
2020
Unsupervised home spirometry with the platform is found equivalent to in-clinic spirometry
2020
NuvoAir with unsupervised in-app coaching meets ATS/ERS repeatability criteria for both pediatric CF and bronchiectasis patients
2020
Swedish pilot shows technology can be used at home by children with CF with postive experience of virtual clinics
2020
Proven effective in driving virtual consultations during an 18-month patient research
2020
Pilot Study with Göteborg, Respiratory Medicine confirms NuvoAir Platform well complements CF care
2020
NuvoAir Reduced Booked and Urgent Face to Face Consultations in Cystic Fibrosis Patients
2020
Pilot study with Royal Brompton Hospital suggests NuvoAir platform may improve Cystic Fibrosis outcomes
2019


Validation of the Technology

Air Next supports Kazakhstan Academy of Preventive Medicine in assessing lung function changes in a COPD patient population
2020
Validation of Air Next spirometer in patients with different respiratory diseases
2020
200 patient study validates Air Next against Gold standard spirometry
2019
NuvoAir technology chosen for lung function monitoring in ALS study
2019
NuvoAir technology supports 26 300 COPD patient study in Germany
2019
200 patient study at Tygerberg Academic Hospital, Cape Town, South Africa validates NuvoAir spirometry technology
2019
200 patient study at University Hospital Complex of Vigo, Spain validates NuvoAir spirometry technology
2018

Real-World-Data from our cystic fibrosis engagements reveals great health economic outcome potential and staggering acceptance

Booked
Consultations

Urgent
Consultations


Improved
understanding of CF

Improved
medication adherence

ePS1.07 Patient experience of virtual consultations: survey results, Journal of Cystic Fibrosis Volume 19, Supplement 2, June 2020, Page s39

9.4

Acceptance of NuvoAir solution on a scale from 0-10

Our partners


Hospitals, universities, pharma companies and CROs around the world have chosen NuvoAir as their respiratory partner. We’re proud to support the work of forward-thinking, innovative players and researchers.

Learn more
Seattle Children's
Dartmouth-Hitchcock
NHS King's College Hospital logo
Boston Children's Hospital
Novartis logo
Roche logo
regeneron logo
NHS Royal Brompton Hospital logo

Join NuvoAir today

We work with leading pharmaceutical companies, insurance plans and healthcare systems to offer NuvoAir at no cost to people with respiratory problems. Answer a few quick questions to see how we can start your journey with NuvoAir.


I'm a patient
I'm a doctor